Lexpos News

Pharmacy owners who plan to start offering appointments on NBS for the Meningococcal B (MenB) Vaccination Service from the service commencement date (20th July 2026) must register for the service by next Monday (6th July 2026). Pharmacy owners who register by 6th July 2026, will receive stock in time to administer it to the patient [...]

The post Men B Vacc Service: Registration deadline approaching to commence service from 20th July appeared first on Community Pharmacy England.

5 new products have been added to the ‘Drugs for which Discount is Not Deducted’ (DND) list from 1 July 2026. Community Pharmacy England, on behalf of pharmacy owners, applied to the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA) for these products to be added to the DND [...]

The post 5 products added to the Discount Not Deducted (DND) list from June 2026 appeared first on Community Pharmacy England.

Community Pharmacy England has negotiated a record 254 price concessions for June, making this the fourth consecutive month of record highs, with some further requests still being negotiated. Community Pharmacy England continues to raise the impact of low Drug Tariff prices and dispensing at a loss by pharmacy owners, and the need for margin reforms, [...]

The post Concession numbers still going up, warns CPE appeared first on Community Pharmacy England.

MHRA Class 3 Medicines Recall: Flucloxacillin Capsules BP 500mg (Flamingo Pharma UK Ltd) Drug Alert Number: EL(26)A/32 Date issued: 30 June 2026 Flamingo Pharma UK Ltd have informed the MHRA that certain packs of Flucloxacillin Capsules BP 500mg contain the incorrect PIL. The affected packs contain the PIL for Amoxicillin 500mg Capsules instead of the PIL [...]

The post MHRA Class 3 Medicines Recall: Flucloxacillin Capsules BP 500mg (Flamingo Pharma UK Ltd) appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Gabapentin Relonchem 50mg/ml Oral Solution (Relonchem Limited) Drug alert number: EL(26)A/31 Date issued: 30 June 2026 Relonchem Limited have informed the MHRA that particles have been observed inside some bottles of Gabapentin Relonchem Oral Solution, identified through a customer complaint. DMRC reference number: DMRC- 38460232 Marketing Authorisation Holder: Relonchem [...]

The post MHRA Class 4 Medicines Defect Notification: Gabapentin Relonchem 50mg/ml Oral Solution (Relonchem Limited) appeared first on Community Pharmacy England.